Nisa Investment Advisors LLC increased its holdings in shares of Clovis Oncology (NASDAQ:CLVS – Get Rating) by 12,490.7% during the first quarter, Holdings Channel reports. The fund owned 169,345 shares of the biopharmaceutical company’s stock after acquiring an additional 168,000 shares during the quarter. Nisa Investment Advisors LLC’s holdings in Clovis Oncology were worth $342,000 as of its most recent filing with the Securities and Exchange Commission.
A number of other institutional investors have also made changes to their positions in CLVS. Dupont Capital Management Corp acquired a new position in Clovis Oncology in the 1st quarter valued at $207,000. Sigma Planning Corp grew its holdings in Clovis Oncology by 137.7% in the 1st quarter. Sigma Planning Corp now owns 31,498 shares of the biopharmaceutical company’s stock valued at $64,000 after buying an additional 18,249 shares in the last quarter. Virtus ETF Advisers LLC grew its holdings in Clovis Oncology by 67.1% in the 4th quarter. Virtus ETF Advisers LLC now owns 60,836 shares of the biopharmaceutical company’s stock valued at $165,000 after buying an additional 24,426 shares in the last quarter. Point72 Hong Kong Ltd acquired a new position in Clovis Oncology in the 4th quarter valued at $64,000. Finally, Nuveen Asset Management LLC grew its holdings in Clovis Oncology by 16.6% in the 4th quarter. Nuveen Asset Management LLC now owns 360,888 shares of the biopharmaceutical company’s stock valued at $21,296,000 after buying an additional 51,495 shares in the last quarter. 36.64% of the stock is owned by institutional investors and hedge funds.
Clovis Oncology Stock Performance
CLVS opened at $1.69 on Tuesday. The firm has a market cap of $243.16 million, a P/E ratio of -0.80 and a beta of 0.51. Clovis Oncology has a 52-week low of $0.58 and a 52-week high of $5.24. The business’s fifty day moving average is $1.42 and its 200-day moving average is $1.75.
Analysts Set New Price Targets
CLVS has been the topic of a number of research reports. StockNews.com initiated coverage on Clovis Oncology in a report on Thursday, March 31st. They issued a “hold” rating on the stock. HC Wainwright lowered Clovis Oncology from a “buy” rating to a “neutral” rating in a report on Friday, May 6th.
About Clovis Oncology
Clovis Oncology, Inc, a biopharmaceutical company, focuses on acquiring, developing, and commercializing anti-cancer agents in the United States, Europe, and internationally. Its commercial product includes Rubraca (rucaparib) tablet, a small molecule poly ADP-ribose polymerase inhibitor, used as monotherapy for the treatment of patients with deleterious BRCA mutation associated advanced ovarian cancer, who have been treated with two or more chemotherapies, and selected for therapy by an FDA-approved companion diagnostic for Rubraca.
- Get a free copy of the StockNews.com research report on Clovis Oncology (CLVS)
- Taking a Look at Nvidia’s Stock Amidst The Semiconductor Chip Gut
- Palantir Stock is Showing Signs of Life
- The Institutions Like The Color Of PPG Industries
- What Investors Need to Know to Beat the Market
- Alcoa Is Well-Positioned For 2022 and 2023
Receive News & Ratings for Clovis Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Clovis Oncology and related companies with MarketBeat.com's FREE daily email newsletter.